Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Current Deferred Revenue: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MADHAVBAUG Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
73 GF Score
Price ₹160.30
GF Value ₹228.29
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Vaidyane Ayurved Laboratories Current Deferred Revenue?

Vaidyane Ayurved Laboratories NSE:MADHAVBAUG 73 Current Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 73/100 and a GF Value™ of ₹228.29 (Possible Value Trap). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Vaidyane Ayurved Laboratories's current deferred revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.

Vaidyane Ayurved Laboratories Current Deferred Revenue Related Terms

Vaidyane Ayurved Laboratories Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Vaidyane Ayurved Laboratories's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaidyane Ayurved Laboratories Current Deferred Revenue Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MADHAVBAUG
73GF Score
Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Current Deferred Revenue of ₹0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Vaidyane Ayurved Laboratories and its competitors.
Is Vaidyane Ayurved Laboratories' Current Deferred Revenue too high?
Vaidyane Ayurved Laboratories' current Current Deferred Revenue is ₹0 Mil. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Current Deferred Revenue compare to ZTS?
Vaidyane Ayurved Laboratories' Current Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Vaidyane Ayurved Laboratories and its competitors. Vaidyane Ayurved Laboratories's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Possible Value Trap. The stock's GF Value™ is ₹228.29, compared to a current price of ₹160.30 — trading 29.8% below its estimated fair value. The current Current Deferred Revenue is ₹0 Mil. Vaidyane Ayurved Laboratories' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Current Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?

Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued. The current stock price of ₹160.30 is trading 29.8% below its estimated GF Value™ of ₹228.29. GuruFocus considers Vaidyane Ayurved Laboratories to be Possible Value Trap.

Key valuation signals for NSE:MADHAVBAUG:

  • Current Deferred Revenue: ₹0 Mil
  • GF Value™: ₹228.29 vs. price of ₹160.30 (29.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaidyane Ayurved Laboratories Business Description

Address 201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
73GF Score

Get the complete analysis for NSE:MADHAVBAUG

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹160.30
Price
₹228.29
GF Value